Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print April 23, 2008, doi:10.1212/01.wnl.0000304039.11891.29)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000304039.11891.29v1
70/24/2277    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gan-Or, Z.
Right arrow Articles by Orr-Urtreger, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gan-Or, Z.
Right arrow Articles by Orr-Urtreger, A.
Received August 15, 2007
Accepted October 22, 2007

Genotype—phenotype correlations between GBA mutations and Parkinson disease risk and onset

Z. Gan-Or , N. Giladi MD, U. Rozovski MD, C. Shifrin MSc, S. Rosner MD, T. Gurevich MD, A. Bar-Shira PhD, and A. Orr-Urtreger MD, PhD*

From The Genetic Institute (Z.G.-O., U.R., C.S., S.R., A.B.-S., A.O.-U.) and Movement Disorders Unit, Parkinson Center, Department of Neurology (N.G., C.S., T.G.), Tel-Aviv Sourasky Medical Center; and The Sackler Faculty of Medicine (Z.G.-O., N.G., C.S., T.G., A.O.-U.), Tel-Aviv University, Israel.


* To whom correspondence should be addressed. E-mail: aviorr{at}tasmc.health.gov.il.

Background: Mutations in GBA and LRRK2 genes have been implicated in Parkinson disease (PD), particularly in Ashkenazi Jews.

Methods: An Israeli Ashkenazi cohort of 420 patients with PD, 333 elderly controls, and 3,805 young controls was screened for eight GBA mutations, which are associated with mild (N370S, R496H) and severe (84GG, IVS2 + 1, V394L, D409H, L444P, RecTL) Gaucher disease. Patients with PD and elderly controls were also genotyped for LRRK2 G2019S.

Results: GBA carrier frequency was 17.9% in patients with PD compared to 4.2% in elderly and 6.35% in young controls. The proportion of severe mutation carriers among patients with PD-GBA carriers was 29% compared to 7% among young controls. Severe and mild GBA mutations increased the risk of developing PD by 13.6- and 2.2-fold, and affected the average age at PD onset (AAO), 55.7 and 57.9 years, compared to 60.7 years in patients without known GBA or LRRK2 mutations.

Conclusions: These data demonstrate genotype-phenotype correlations between different GBA mutations and Parkinson disease (PD) risk and AAO in Ashkenazi Jews. Additionally, an earlier AAO was observed in LRRK2 G2019S carrier patients with PD. Finally, these data demonstrate that a surprisingly high frequency, more than one third of our patient population, carried a mutation in GBA or LRRK2.




This article has been cited by other articles:


Home page
 NEJMHome page
E. Sidransky, M.A. Nalls, J.O. Aasly, J. Aharon-Peretz, G. Annesi, E.R. Barbosa, A. Bar-Shira, D. Berg, J. Bras, A. Brice, et al.
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
N. Engl. J. Med., October 22, 2009; 361(17): 1651 - 1661.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
Z. Gan-Or, N. Giladi, and A. Orr-Urtreger
Differential phenotype in Parkinson's disease patients with severe versus mild GBA mutations
Brain, October 1, 2009; 132(10): e125 - e125.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. H. B. Maegawa, M. B. Tropak, J. D. Buttner, B. A. Rigat, M. Fuller, D. Pandit, L. Tang, G. J. Kornhaber, Y. Hamuro, J. T. R. Clarke, et al.
Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease
J. Biol. Chem., August 28, 2009; 284(35): 23502 - 23516.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. Neumann, J. Bras, E. Deas, S. S. O'Sullivan, L. Parkkinen, R. H. Lachmann, A. Li, J. Holton, R. Guerreiro, R. Paudel, et al.
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease
Brain, July 1, 2009; 132(7): 1783 - 1794.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. B. Leverenz, O. L. Lopez, and S. T. DeKosky
The Expanding Role of Genetics in the Lewy Body Diseases: The Glucocerebrosidase Gene
Arch Neurol, May 1, 2009; 66(5): 555 - 556.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
J. Mitsui, I. Mizuta, A. Toyoda, R. Ashida, Y. Takahashi, J. Goto, Y. Fukuda, H. Date, A. Iwata, M. Yamamoto, et al.
Mutations for Gaucher Disease Confer High Susceptibility to Parkinson Disease
Arch Neurol, May 1, 2009; 66(5): 571 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
L. N. Clark, L. A. Kartsaklis, R. Wolf Gilbert, B. Dorado, B. M. Ross, S. Kisselev, M. Verbitsky, H. Mejia-Santana, L. J. Cote, H. Andrews, et al.
Association of Glucocerebrosidase Mutations With Dementia With Lewy Bodies
Arch Neurol, May 1, 2009; 66(5): 578 - 583.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
S. Lesage and A. Brice
Parkinson's disease: from monogenic forms to genetic susceptibility factors
Hum. Mol. Genet., April 15, 2009; 18(R1): R48 - R59.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
S. Tang, Z. Zhang, G. Kavitha, E.-K. Tan, and S. K. Ng
MDPD: an integrated genetic information resource for Parkinson's disease
Nucleic Acids Res., January 1, 2009; 37(suppl_1): D858 - D862.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
E. Rogaeva and J. Hardy
Gaucher and Parkinson diseases: Unexpectedly related
Neurology, June 10, 2008; 70(24): 2272 - 2273.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by AAN Enterprises, Inc.